Prothena reports FY2024 net loss $122.3M; cash $472.2M; AFFIRM-AL topline expected Q2 2025

PROTHENA CORP PUBLIC LTD CO

2024-FY EPS reported -$2.27 revenue$135,157,000

Net loss per share Q4 $1.08, FY2024 $2.27; total revenue FY2024 $135.2M (up from $91.4M prior year).
Cash $472.2M at Dec 31, 2024, no debt; 2025 guidance: net cash burn $168-175M, year-end cash ≈$301M.
Confirmatory Phase 3 AFFIRM-AL (birtamimab) topline results expected Q2 2025; SPA with FDA, primary endpoint all-cause mortality.
PRX012 Phase 1 ASCENT readouts starting mid-2025; BMS started Phase 2 for BMS-986446; $80M received for PRX019 license.
Roche's prasinezumab Phase 2b PADOVA missed primary endpoint but showed trends; Roche to discuss next steps with health authorities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.